[Ciprofloxacin in the treatment of chronic bacterial prostatitis].
17 exacerbation and 13 latent CBP cases received ciprofloxacin in a dose 500 mg twice a day orally for 6-34 days. At pretreatment microbiological investigation of the prostatic juice 49 cultures of 7 microorganism species were isolated (12 cases of monoculture, 18 cases of 2-component associations). S. epidermidis and E. faecalis occurred more frequently (in 29.4 and 25%, respectively). Ciprofloxacin was highly active against all the isolated agents and by the number of sensitive to it strains proved superior to control antimicrobial drugs. Good and satisfactory treatment outcomes were achieved in 76.8% of patients. Side effects recorded in 8 patients (26.6%) caused the drug undue discontinuation in 1 patient only.
Trapeznikova
M F
MF
Savitskaia
K I
KI
al-Suri
A
A
Nekhorosheva
A G
AG
Abramian
N S
NS
Nasonov
V N
VN
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001437:Bacteriuria / Q000188:drug therapy / Q000382:microbiology; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011467:Prostate / Q000378:metabolism / Q000382:microbiology; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D002939:Ciprofloxacin
Tsiprofloksatsin pri lechenii khronicheskogo bakterial'nogo prostatita.